Table 3.
HIV-related behaviour outcome | Poly drug use (past 3 months) | Chemsex drug use (past 3 months) | ||||
Unadjusted PR (95% CI) P value* |
Adjusted (i) PR (95% CI) P value* |
Adjusted (ii) PR (95% CI) P value* |
Unadjusted PR (95% CI) P value* |
Adjusted (i) PR (95% CI) P value* |
Adjusted (ii) PR (95% CI) P value* |
|
CLS with one or more partners (past 3 months) | 1.30 (1.20 to 1.40) | 1.31 (1.21 to 1.42) | 1.31 (1.21 to 1.41) | 1.32 (1.23 to 1.43) | 1.33 (1.23 to 1.44) | 1.33 (1.23 to 1.44) |
<0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
CLS with two or more partners (past 3 months) | 1.91 (1.64 to 2.24) | 1.93 (1.65 to 2.25) | 1.91 (1.63 to 2.23) | 1.95 (1.67 to 2.28) | 1.95 (1.67 to 2.28) | 1.94 (1.66 to 2.27) |
<0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
CLS with unknown/HIV-positive partner (past 3 months) | 1.71 (1.44 to 2.03) | 1.69 (1.43 to 2.02) | 1.71 (1.43 to 2.03) | 1.83 (1.54 to 2.17) | 1.81 (1.52 to 2.16) | 1.82 (1.53 to 2.16) |
<0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
Receptive CLS with unknown status partner (past 3 months) | 1.37 (0.98 to 1.89) | 1.34 (0.97 to 1.87) | 1.34 (0.97 to 1.85) | 1.36 (0.98 to 1.89) | 1.34 (0.97 to 1.86) | 1.34 (0.97 to 1.85) |
0.062 | 0.07 | 0.08 | 0.07 | 0.08 | 0.08 | |
Bacterial STI diagnosis (past year) | 1.65 (1.43 to 1.91) | 1.66 (1.44 to 1.91) | 1.66 (1.43 to 1.91) | 1.69 (1.43 to 1.91) | 1.66 (1.43 to 1.91) | 1.65 (1.43 to 1.91) |
<0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
Eleven or more new sexual partners (past year) | 1.64 (1.43 to 1.89) | 1.62 (1.41 to 1.86) | 1.61 (1.39 to 1.85) | 1.61 (1.39 to 1.85) | 1.56 (1.36 to 1.79) | 1.55 (1.35 to 1.78) |
<0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
Group sex (past 3 months) | 2.41 (2.11 to 2.75) | 2.38 (2.08 to 2.72) | 2.38 (2.09 to 2.73) | 2.39 (2.09 to 2.75) | 2.39 (2.09 to 2.74) | 2.39 (2.09 to 2.74) |
<0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
PEP use (past year) | 2.16 (1.72 to 2.71) | 2.15 (1.71 to 2.71) | 2.16 (1.72 to 2.72) | 2.47 (1.95 to 3.11) | 2.43 (1.93 to 3.08) | 2.44 (1.93 to 3.08) |
<0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
PrEP use (past year) | 2.46 (1.49 to 4.01) | 2.54 (1.54 to 4.19) | 2.69 (1.64 to 4.43) | 2.13 (1.29 to 3.52) | 2.28 (1.39 to 3.71) | 2.38 (1.46 to 3.86) |
<0.001 | <0.001 | <0.001 | 0.003 | 0.001 | <0.001 | |
Recent HIV test (within past 6 months) | 1.16 (1.08 to 1.25) | 1.16 (1.08 to 1.25) | 1.17 (1.09 to 1.26) | 1.18 (1.10 to 1.26) | 1.18 (1.10 to 1.27) | 1.18 (1.11 to 1.27) |
<0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Adjusted model (i) age (continuous variable), ethnicity, sexual identity, university education, ongoing relationship status.
Adjusted model (ii) age (continuous variable), ethnicity, sexual identity, university education, ongoing relationship status, higher-risk drinking, depressive symptoms (PHQ-9 ≥10) (missing values included in variables for adjusted models).
*P values by Wald test.
AURAH2, Attitudes to and Understanding Risk of Acquisition of HIV over Time; CLS, condomless sex; MSM, men who have sex with men; PEP, post-exposure prophylaxis; PrEP, pre-exposure prophylaxis.